

Clinical Policy: Dasabuvir/Ombitasvir/Paritaprevir/Ritonavir (Viekira Pak)

Reference Number: CP.CPA.288

Effective Date: 11.01.16

Last Review Date: 08.24

Line of Business: Commercial

[Revision Log](#)

See [Important Reminder](#) at the end of this policy for important regulatory and legal information.

Description

Dasabuvir/paritaprevir/ritonavir/ombitasvir (Viekira Pak[®]) is a combination of ombitasvir, a hepatitis C virus (HCV) NS5A inhibitor, paritaprevir, an HCV NS3/4A protease inhibitor, ritonavir, a CYP3A inhibitor and dasabuvir, an HCV non-nucleoside NS5B polymerase inhibitor.

FDA Approved Indication(s)

Viekira Pak is indicated for the treatment of adult patients with chronic HCV:

- Genotype 1b without cirrhosis or with compensated cirrhosis
- Genotype 1a without cirrhosis or with compensated cirrhosis for use in combination with ribavirin (RBV)

Policy/Criteria

Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria.

It is the policy of health plans affiliated with Centene Corporation[®] that Viekira Pak is **medically necessary** when the following criteria are met:

I. Initial Approval Criteria**A. Hepatitis C Infection** (must meet all):

1. Diagnosis of HCV infection as evidenced by detectable serum HCV RNA levels by quantitative assay in the last 6 months;
2. Confirmed HCV genotype is 1;
**Chart note documentation and copies of lab results are required*
3. Prescribed by or in consultation with a gastroenterologist, hepatologist or infectious disease specialist, or provider who has expertise in treating HCV based on a certified training program (*see Appendix F*);
4. Age $\geq$ 18 years;
5. If cirrhosis is present, confirmation of Child-Pugh A status;
6. Member must use **brand Epclusa[®]**, unless contraindicated or clinically significant adverse effects are experienced (*see Appendix E*);*
**Coadministration with omeprazole up to 20 mg is not considered acceptable medical justification for inability to use Epclusa*
7. Life expectancy $\geq$ 12 months with HCV treatment;
8. Prescribed regimen is consistent with an FDA or AASLD-IDSA recommended regimen (*see Section V Dosage and Administration for reference*);

9. If HCV/HIV-1 co-infection, member is or will be on a suppressive antiretroviral drug regimen to reduce the risk of HIV-1 protease inhibitor drug resistance;
10. Dose does not exceed ombitasvir/paritaprevir/ritonavir 12.5 mg/75 mg/50 mg (2 tablets) once daily and dasabuvir 250 mg (1 tablet) twice daily.

Approval duration: up to a total of 12 weeks*

(*Approved duration should be consistent with a regimen in Section V Dosage and Administration)

B. Other diagnoses/indications (must meet all):

1. Member must use **brand Epclusa**, if applicable for the requested indication, unless contraindicated or clinically significant adverse effects are experienced
2. One of the following (a or b):
 - a. If this drug has recently (within the last 6 months) undergone a label change (e.g., newly approved indication, age expansion, new dosing regimen) that is not yet reflected in this policy, refer to one of the following policies (i or ii):
 - i. For drugs on the formulary (commercial, health insurance marketplace) or PDL (Medicaid), the no coverage criteria policy for the relevant line of business: CP.CPA.190 for commercial; or
 - ii. For drugs NOT on the formulary (commercial, health insurance marketplace) or PDL (Medicaid), the non-formulary policy for the relevant line of business: CP.CPA.190 for commercial; or
 - b. If the requested use (e.g., diagnosis, age, dosing regimen) is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized) AND criterion 2a above does not apply, refer to the off-label use policy for the relevant line of business: CP.CPA.09 for commercial.

II. Continued Therapy

A. Hepatitis C Infection (must meet all):

1. Member meets one of the following (a, b, or c):
 - a. Currently receiving medication via Centene benefit or member has previously met initial approval criteria;
 - b. Member is currently receiving medication and is enrolled in a state and product with continuity of care regulations (*refer to state specific addendums for CC.PHARM.03A and CC.PHARM.03B*);
 - c. Must meet both of the following (i and ii):
 - i. Documentation supports that member is currently receiving Viekira Pak for HCV infection and has recently completed at least 60 days of treatment with Viekira Pak;
 - ii. Confirmed HCV genotype is 1;
2. Member is responding positively to therapy;
3. Dose does not exceed ombitasvir/paritaprevir/ritonavir 12.5 mg/75 mg/50 mg (2 tablets) once daily and dasabuvir 250 mg (1 tablet) twice daily.

Approval duration: up to a total of 12 weeks*

(*Approved duration should be consistent with a regimen in Section V Dosage and Administration)

B. Other diagnoses/indications (must meet 1 or 2):

1. If this drug has recently (within the last 6 months) undergone a label change (e.g., newly approved indication, age expansion, new dosing regimen) that is not yet reflected in this policy, refer to one of the following policies (a or b):
 - a. For drugs on the formulary (commercial, health insurance marketplace) or PDL (Medicaid), the no coverage criteria policy for the relevant line of business: CP.CPA.190 for commercial; or
 - b. For drugs NOT on the formulary (commercial, health insurance marketplace) or PDL (Medicaid), the non-formulary policy for the relevant line of business: CP.CPA.190 for commercial; or
2. If the requested use (e.g., diagnosis, age, dosing regimen) is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized) AND criterion 1 above does not apply, refer to the off-label use policy for the relevant line of business: CP.CPA.09 for commercial.

III. Diagnoses/Indications for which coverage is NOT authorized:

- A. Non-FDA approved indications, which are not addressed in this policy, unless there is sufficient documentation of efficacy and safety according to the off-label use policy – CP.CPA.09 for commercial or evidence of coverage documents.

IV. Appendices/General Information

Appendix A: Abbreviation/Acronym Key

AASLD: American Association for the Study of Liver Diseases
DAA: direct-acting antiviral
FDA: Food and Drug Administration
HBV: hepatitis B virus
HCV: hepatitis C virus
HIV: human immunodeficiency virus

IDSA: Infectious Diseases Society of America
NS3/4A, NS5A/B: nonstructural protein
PegIFN: pegylated interferon
RBV: ribavirin
RNA: ribonucleic acid
SVR12: sustained virologic response at 12 weeks

Appendix B: Therapeutic Alternatives

This table provides a listing of preferred alternative therapy recommended in the approval criteria. The drugs listed here may not be a formulary agent for all relevant lines of business and may require prior authorization.

Drug Name	Dosing Regimen	Dose Limit/ Maximum Dose
sofosbuvir/ velpatasvir (Epclusa®)	Treatment-naïve or treatment-experienced without cirrhosis or with compensated cirrhosis: Genotype 1 One tablet PO QD for 12 weeks	sofosbuvir 400 mg/ velpatasvir 100 mg (1 tablet) per day

Therapeutic alternatives are listed as Brand name® (generic) when the drug is available by brand name only and generic (Brand name®) when the drug is available by both brand and generic.

Appendix C: Contraindications/Boxed Warnings

- Contraindication(s): Viekira Pak is contraindicated in:
 - Patients with moderate to severe hepatic impairment (Child-Pugh B and C) due to risk of potential toxicity.
 - If Viekira is administered with RBV, the contraindications to RBV also apply to this combination regimen. Refer to the RBV prescribing information for a list of contraindications for RBV.
 - Co-administration with drugs that are:
 - Highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with serious and/or life-threatening events.
 - Moderate or strong inducers of CYP3A and strong inducers of CYP2C8 and may lead to reduced efficacy of Viekira Pak.
 - Strong inhibitors of CYP2C8 and may increase dasabuvir plasma concentrations and the risk of QT prolongation.
 - Patients with known hypersensitivity to ritonavir (e.g., toxic epidermal necrolysis (TEN) or Stevens-Johnson syndrome).
- Boxed warning(s): risk of hepatitis B (HBV) virus reactivation in patients coinfecting with HCV and HBV

Appendix D: Direct-Acting Antivirals for Treatment of HCV Infection

Brand Name	Drug Class				
	NS5A Inhibitor	Nucleotide Analog NS5B Polymerase Inhibitor	Non-Nucleoside NS5B Palm Polymerase Inhibitor	NS3/4A Protease Inhibitor (PI)	CYP3A Inhibitor
Epclusa*	Velpatasvir	Sofosbuvir			
Harvoni*	Ledipasvir	Sofosbuvir			
Mavyret*	Pibrentasvir			Glecaprevir	
Sovaldi		Sofosbuvir			
Viekira Pak*	Ombitasvir		Dasabuvir	Paritaprevir	Ritonavir
Vosevi*	Velpatasvir	Sofosbuvir		Voxilaprevir	
Zepatier*	Elbasvir			Grazoprevir	

*Combination drugs

Appendix E: General Information

- Acceptable medical justification for inability to use Epclusa (preferred product):
 - In patients indicated for co-administration of Epclusa with ribavirin: contraindications to ribavirin.
 - In patients indicated for co-administration with amiodarone: serious symptomatic bradycardia in patients taking amiodarone, with cardiac monitoring recommended.
- Unacceptable medical justification for inability to use Epclusa (preferred product):
 - Co-administration with omeprazole up to 20 mg is not considered acceptable medical justification for inability to use Epclusa.

- Per the Epclusa Prescribing Information: “If it is considered medically necessary to coadminister, Epclusa should be administered with food and taken 4 hours before omeprazole 20 mg.”
- HBV reactivation is a Black Box Warning for all direct-acting antiviral drugs for the treatment of HCV. HBV reactivation has been reported when treating HCV for patients co-infected with HBV, leading to fulminant hepatitis, hepatic failure, and death, in some cases. Patients should be monitored for HBV reactivation and hepatitis flare during HCV treatment and post-treatment follow-up, with treatment of HBV infection as clinically indicated.
- For patients with HCV/HIV-1 (human immunodeficiency virus type-1) co-infection, the patient should be on a suppressive antiretroviral drug regimen to reduce the risk of HIV-1 protease inhibitor drug resistance.
- Child-Pugh Score:

	1 Point	2 Points	3 Points
Bilirubin	Less than 2 mg/dL Less than 34 umol/L	2-3 mg/dL 34-50 umol/L	Over 3 mg/dL Over 50 umol/L
Albumin	Over 3.5 g/dL Over 35 g/L	2.8-3.5 g/dL 28-35 g/L	Less than 2.8 g/dL Less than 28 g/L
INR	Less than 1.7	1.7 - 2.2	Over 2.2
Ascites	None	Mild / medically controlled	Moderate-severe / poorly controlled
Encephalopathy	None	Mild / medically controlled Grade I-II	Moderate-severe / poorly controlled. Grade III-IV

Child-Pugh class is determined by the total number of points: A = 5-6 points; B = 7-9 points; C = 10-15 points.

- The AASLD/IDSA HCV Guidance as of March 2021 carries no Viekira Pak recommendations for any genotype.

Appendix F: Healthcare Provider HCV Training

Acceptable HCV training programs and/or online courses include, but are not limited to the following:

- Hepatitis C online course (<https://www.hepatitisc.uw.edu/>): University of Washington is funded by the Division of Viral Hepatitis to develop a comprehensive, online self-study course for medical providers on diagnosis, monitoring, and management of hepatitis C virus infection. Free CME and CNE credit available.
- Fundamentals of Liver Disease (<https://liverlearning.aasld.org/fundamentals-of-liver-disease>): The AASLD, in collaboration with ECHO, the American College of Physicians (ACP), CDC, and the Department of Veterans Affairs, has developed Fundamentals of Liver Disease, a free, online CME course to improve providers’ knowledge and clinical skills in hepatology.
- Clinical Care Options: <http://www.clinicaloptions.com/hepatitis.aspx>
- CDC training resources: <https://www.cdc.gov/hepatitis/resources/professionals/trainingresources.htm>

Appendix G: Incomplete Adherence and AASLD-IDSA Recommended Management of Treatment Interruptions

- There are minimal data regarding the outcome of patients who have incomplete adherence to DAA therapy or the threshold level of adherence below which the incidence of sustained virologic response at 12 weeks (SVR12) is significantly reduced. In general, a treatment interruption of < 7 days is unlikely to impact SVR12.
- There are few data on which to base recommendations regarding how to manage patients who have discontinued DAAs for several days to weeks. The below recommendations are applicable to treatment-naïve patients with HCV, without cirrhosis or with compensated cirrhosis, *receiving either Mavyret or Epclusa*. Patients with prior DAA treatment, or receiving other DAA treatment regimens, or other populations (e.g., patients who are posttransplant or have decompensated cirrhosis) should be managed in consultation with an expert.
 - Interruptions during the first 28 days of DAA therapy:
 - If missed ≤ 7 days, restart DAA therapy immediately and complete therapy for originally planned duration (8 or 12 weeks).
 - If missed ≥ 8 days, restart DAA therapy immediately and obtain HCV RNA test as soon as possible. If HCV RNA is negative, complete originally planned DAA treatment course (8 or 12 weeks). Recommendation to extend DAA treatment for an additional 4 weeks for patients with genotype 3 and/or cirrhosis. If HCV RNA is positive or not obtained, extend DAA treatment for an additional 4 weeks.
 - Interruptions after receiving ≥ 28 days of DAA therapy:
 - If missed ≤ 7 days, restart DAA therapy immediately and complete therapy for originally planned duration (8 or 12 weeks).
 - If missed 8-20 consecutive days, restart DAA therapy immediately and obtain HCV RNA test as soon as possible. If HCV RNA is negative, complete originally planned DAA treatment course (8 or 12 weeks). Recommendation to extend DAA treatment for an additional 4 weeks for patients with genotype 3 and/or cirrhosis. If HCV RNA is positive or not obtained, stop treatment and retreat according to the recommendations in the AASLD-IDSA Retreatment Section.
 - If missed ≥ 21 consecutive days, stop DAA treatment and assess for SVR12. If SVR12 not achieved, retreat according to the recommendations in the AASLD-IDSA Retreatment Section.

V. Dosage and Administration

Indication: HCV	Dosing Regimen	Maximum Dose	Reference
Genotype 1a: Treatment-naïve or interferon-experienced without cirrhosis	Viekira Pak plus weight-based RBV for 12 weeks	Viekira Pak: paritaprevir 150 mg /ritonavir 100 mg/ ombitasvir 25 mg per day; dasabuvir 500 mg per day	FDA-approved labeling

Indication: HCV	Dosing Regimen	Maximum Dose	Reference
Genotype 1a: Treatment-naïve or interferon-experienced with compensated cirrhosis	Viekira Pak plus weight-based RBV for 24 weeks* *In some patients, the treatment duration may be reduced to 12 weeks based on patient's prior treatment history		
Genotype 1b: Treatment-naïve or interferon-experienced with or without compensated cirrhosis	Viekira Pak for 12 weeks		

AASLD/IDSA treatment guidelines for hepatitis C infection are updated at irregular intervals; refer to the most updated AASLD/IDSA guideline for most accurate treatment regimen.

The AASLD/IDSA HCV guidance no longer recommends use of Viekira Pak

VI. Product Availability

- Tablet: paritaprevir 75 mg, ritonavir 50 mg, ombitasvir 12.5 mg
- Tablet: dasabuvir 250 mg

**Viekira Pak is dispensed in a monthly carton for a total of 28 days of therapy. Each monthly carton contains four weekly cartons. Each weekly carton contains seven daily dose packs.*

VII. References

1. Viekira Pak Prescribing Information. North Chicago, IL: Abbvie Pharmaceuticals Corp; December 2019. Available at https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/206619s020lbl.pdf. Accessed May 8, 2024.
2. American Association for the Study of Liver Diseases/ Infectious Disease Society of America (AASLD-IDSA). HCV guidance: recommendations for testing, managing, and treating hepatitis C. Last updated December 19, 2023. Available at: <https://www.hcvguidelines.org/>. Accessed May 20, 2024.
3. CDC. Clinical Overview of Hepatitis C. Last updated November 7, 2023. Available at: <https://www.cdc.gov/hepatitis-c/hcp/clinical-overview>. Accessed May 20, 2024.

Reviews, Revisions, and Approvals	Date	P&T Approval Date
3Q 2020 annual review: removed discontinued Viekira XR from policy; added requirements for new prescriber to include a “provider who has expertise in treating HCV based on a certified training program,” life expectancy of 12 months or greater, and adherence	04.30.20	08.20

Reviews, Revisions, and Approvals	Date	P&T Approval Date
program to align with Hepatitis C policies; added requirement for suppressive antiretroviral drug regimen if HIV-1 co-infection per PI to align with Viekira Pak policies; references reviewed and updated.		
Revised redirection to only include Epclusa authorized generic and Mavyret (Harvoni AG 8 weeks and Zepatier no longer preferred) per June SDC and prior clinical guidance.	07.14.20	
Per September SDC and prior clinical guidance for 1/1/21 effective, revised redirection to require brand Epclusa or Vosevi.	09.22.20	
2Q 2021 annual review: no significant changes; references reviewed and updated.	02.14.21	05.21
3Q 2021 annual review: no significant changes; added clarification that the brand version of Epclusa is the preferred alternative; Vosevi removed as possible redirection as it shares no common indications with Viekira and therefore cannot be an alternative; included reference to Appendix E with addition of contraindications that would warrant bypassing preferred agent; updated Appendix B therapeutic alternatives; references reviewed and updated.	05.10.21	08.21
3Q 2022 annual review: no significant changes; clarified initial auth duration is “up to a total of” 12 weeks; added omeprazole coadministration as unacceptable rationale for not using preferred Epclusa to criteria and Appendix E; references reviewed and updated.	07.20.22	08.22
Template changes applied to other diagnoses/indications and continued therapy section.	09.23.22	
3Q 2023 annual review: eliminated adherence program participation criterion since member is already being managed by an HCV-trained specialist and due to competitor analysis; added preferred redirections to other diagnoses/indications initial criteria section; references reviewed and updated.	04.12.23	08.23
3Q 2024 annual review: removed qualifier of “chronic” from HCV criteria as AASLD-IDSA recommends treatment of both acute and chronic HCV; removed “preferred” from brand Epclusa redirection; added Appendix G for guidance on incomplete adherence and AASLD-IDSA recommended management of treatment interruptions; references reviewed and updated.	05.30.24	08.24

Important Reminder

This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. The Health Plan makes no representations and accepts no liability with respect to the content of any external information used or relied upon in

developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved. “Health Plan” means a health plan that has adopted this clinical policy and that is operated or administered, in whole or in part, by Centene Management Company, LLC, or any of such health plan’s affiliates, as applicable.

The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions, and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable Health Plan-level administrative policies and procedures.

This clinical policy is effective as of the date determined by the Health Plan. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. The Health Plan retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.

This clinical policy does not constitute medical advice, medical treatment, or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members. This clinical policy is not intended to recommend treatment for members. Members should consult with their treating physician in connection with diagnosis and treatment decisions.

Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom the Health Plan has no control or right of control. Providers are not agents or employees of the Health Plan.

This clinical policy is the property of the Health Plan. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, members, and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, members and their representatives agree to be bound by such terms and conditions by providing services to members and/or submitting claims for payment for such services.

©2016 Centene Corporation. All rights reserved. All materials are exclusively owned by Centene Corporation and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Centene Corporation. You may not alter or remove any trademark, copyright or other notice contained herein. Centene® and Centene Corporation® are registered trademarks exclusively owned by Centene Corporation.